HTA CONFERENCE

HTA implementation in Greece: A 3 years' experience from the industry perspective

Olympios Papadimitriou, SfEE President, General Manager Novo Nordisk






March 23, 2021

ΣfEE
ΣΥΝΔΕΣΜΟΣ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΕΠΙΧΕΙΡΗΣΕΩΝ ΕΛΛΑΔΟΣ

EU HTA principles

Deliver access to innovative treatments, while ensuring the financial sustainability of healthcare systems

Through cross-country collaborations, or through national procedures

A well-functioning European capacity for joint assessments is essential. Europe needs to speak with a coherent voice on clinical evidence

An improved cooperation for generating evidence among the European regulatory authorities and the responsible HTA institutions, is essential

A system that improves the availability of innovative technologies for patients. Delays, inconsistencies and duplications should not be an option.

HTA in Greece | Current situation

Greece introduced HTA (& Negotiation) Committee with delay

The Committee is understaffed

Delays in the processes – no new drugs for 2 years

Although output is improving, results so far are not satisfactory

Consequently, patients have reduced access to new treatments

HTA in Greece | Current situation

The creation of the necessary bodies is not usually accompanied by their proper functioning and - in the end - the needs of the patients are not covered in time

SfEE HTA proposals

- Formation of an HTA Organization with sufficient resources
- A regular operational flow and timeline has to be ensured
- Transparency, in the standards of other European countries, in all procedures and information on the course of work
- Immediate legislative changes to the framework for the appointment of external assessors, with a view to avoiding conflicts of interest
- HTA register of submissions and decisions with publication of the line listing
- Fast track procedure of well established products, known active substances for existing indications, orphan drugs and indications, hybrid products
- Make the necessary data available to MAHs, in a timely manner

HTA should not be used as an official "access delay mechanism"

What are the consequences for missing deadlines?



An ultra-distorted use of the negotiation process

	ExFactory price	Offered MAH discount in negotiation process %	Offered MAH discount in negotiation process €	Retail price	Patient co-payment	Cost for EOPYY	Discount that MAH should offer to match the cost for EOPYY
Without negotiation	20,0	0%	0,00	29,0	25%	21,7	
With negotiation	20,0	1%	0,20	29,0	12,50%	25,3	18,1%
Without negotiation	20,0	0%	0,00	29,0	10%	26,1	
With negotiation	20,0	1%	0,20	29,0	5,00%	27,5	7,2%

Can HTA co-exist with the clawback concept?

Ensure access to new medicines

Patients across Europe are living longer, healthier and more productively, thanks to innovative medicines

More than 7,000 drugs under development - new wave of medical innovation

European health systems need to be prepared and reformed to ensure rapid and sustainable access to this innovation

For Greece, it is a great challenge to adopt all this innovation

Regulators, health system partners, industry, and government should collaborate to ensure access and availability of new medicines

Thank you!

Olympios Papadimitriou,
SfEE President,
General Manager Novo Nordisk